Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 449Carcinoma, Non-Small-Cell Lung 372Neoplasms 349Prostatic Neoplasms 285Colorectal Neoplasms 273Multiple Myeloma 211Lung Neoplasms 201Neoplasm Metastasis 185Leukemia, Myeloid, Acute 163Ovarian Neoplasms 159Pancreatic Neoplasms 155Squamous Cell Carcinoma of Head and Neck 140Melanoma 131Recurrence 108Glioblastoma 105Head and Neck Neoplasms 103Carcinoma, Renal Cell 103Endometrial Neoplasms 100Precursor Cell Lymphoblastic Leukemia-Lymphoma 97Lymphoma, Non-Hodgkin 95Stomach Neoplasms 94Carcinoma, Hepatocellular 94Lymphoma 93Triple Negative Breast Neoplasms 92Brain Neoplasms 90Uterine Cervical Neoplasms 86Lymphoma, Large B-Cell, Diffuse 81Glioma 79Urinary Bladder Neoplasms 78Sarcoma 78

Interventions

temsirolimus 1Vinorelbine 1Vincristine 1Sirolimus 1Radiotherapy 1Radiation 1Irinotecan 1Dactinomycin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Rhabdomyosarcoma, Alveolar × 30 days × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡